Antoni C., Krueger G.G., de Vlam K. et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial // Ann. Rheum. Dis. 2005. 64. (8). 1150-1157.
ARCO (Association Research Circulation Osseous): committee on terminology and classification // ARCO News. 1992. 4. 41-46.
Badokin V.V. Perspectives for the use of TNF-α inhibitors in psoriasis and psoriatic arthritis // Klinicheskaya farmakologiya i terapiya = Clinical pharmacology and therapy. 2005. 14. (1). 76-79. [In Russian].
Badokin V.V. Psoriatic arthritis (clinic, diagnosis, treatment) // Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2006. 44. (2s). 65-77. [In Russian].
Badokin V.V. The tumor necrosis factor-alpha is the main target of pathogenetic therapy of psoriasis and psoriatic arthritis // Dermatologiya = Dermatology. 2006. (1). 27-31. [In Russian].
Bunchuk N.V., Badokin V.V., Korotaeva T.V. Psoriatic arthritis // Rheumatology: national leadership. Moscow: GEOTAR-MEDIA, 2008. 355-366. [In Russian].
Christophers E. Psoriasis - epidemiology and clinical spectrum // Clin. Exp. Dermatol. 2001. 26. (4). 314-320.
Fiocco U., Sfriso P., Oliviero F. et al. Blockade of intra-articular TNF in peripheral spondyloarthritis: its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers // Joint Bone Spine. 2013. 80. 165–170.
Fitzgerald O., Dougados M. Psoriatic arthritis: one or more diseases? // Best Pract. Res. Clin. Rheumatol. 2006. 20. (3). 435-450.
Gladman D.D., Antoni C., Mease P. et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome // Ann. Rheum. Dis. 2005. 64. (Suppl. 2). ii14-ii17.
Haroon M., Gallagher P., Heffernan E. et al. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease // J Rheumatol. 2014. 41. (7). 1357-1365.
Helmick C.G., Lee-Han H., Hirsch S.C. et al. Prevalence of psoriasis among adults in the U.S.: 2003–2006 and 2009–2010 National Health and Nutrition Examination Surveys // Am. J. Prev. Med. 2014. 47. (1). 37–45.
Hussar D.A. New drugs: Golimumab, besifloxacin hydrochloride, and artemether / lumefantrine // J. Am. Pharm. Ass. 2009. 49. (4). 570-573.
Huynh D., Kavanaugh A. Psoriatic arthritis: current therapy and future directions // Expert Opin Pharmacother. 2013. 14. 1755–1764.
Ibrahim G., Waxman R., Helliwell P.S. The prevalence of psoriatic arthritis in people with psoriasis // Arthritis Rheum. 2009. 61. (10). 1373-1378.
Jamnitski A., Symmons D., Peters M.J. et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review // Ann. Rheum. Dis. 2013. 72. (2). 211-216.
Kavanaugh A., Antoni C.E. Gladman D. et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year // 006. 65. (8). 1038-1043.
Kane D., Stafford L., Bresnihan B. et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience // Rheumatology. 2003. 42. (12). 1460-1468.
Kavanaugh A., McInnes I., Mease P. et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis twenty-four-week efficacy and safety results of a randomized, placebo-controlled study // Arthritis Rheum. 2009. 60. (4). 976-986.
Kavanaugh A., McInnes I.B., Mease P. et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study) // Ann. Rheum. Dis. 2014. 73. (9). 1689-1694.
Korotaeva N.V. Results of an evaluation of the efficacy and safety of a new inhibitor of tumor necrosis factor α - golimumab in the treatment of psoriatic arthritis // Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012. (3. Suppl. 3). 17-22. [In Russian].
Lebwohl M. Psoriasis // Lancet. 2003. 361. (9364). 1197-1204.
Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis // Nature. 2007. 445. (7130). 866-873.
Martínez-Ferrer M.A., Peris P., Guañabens N. Osteonecrosis. What is new? // Reumatol. Clin. 2007. 3. (2). 78-84.
Mcdonough E., Ayearst R., Eder L. et al. Depression and anxiety in psoriatic disease: prevalence and associated factors // J. Rheumatol. 2014. 41. (5). 887-896.
McLaughlin M., Ostör A. Early treatment of psoriatic arthritis improves prognosis // Practitioner. 2014. 258. (1777). 21-24.
Mease P.J., Gladman D.D., Ritchlin C.T. et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis - Results of a double-blind, randomized, placebo-controlled trial // Arthritis Rheum. 2005. 52. (10). 3279–3289.
Mease P.J., Kivitz A.J., Burch F.X. et al. Etanercept treatment of psoriatic arthritis - Safety, efficacy, and effect on disease progression // Arthritis Rheum. 2004. 50. (7). 2264-2272.
Menter A., Gottlieb A., Feldman S.R. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics // J. Am. Acad. Dermatol. 2008. 58. (5). 826-850.
Meyer N., Paul C., Feneron D. et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients // J. Eur. Acad. Dermatol. Venereol. 2010. 24. (9). 1075-1082.
Minnock P., Kirwan J., Veale D. et al. Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritis // Clin. Exp. Rheumatol. 2010. 28. (3). 401-404.
Myers W., Opeola M., Gottlieb A.B. Common clinical features and disease mechanisms of psoriasis and psoriatic arthritis // Curr. Rheumatol. Rep. 2004. 6. (4). 306-313.
Nograles K.E., Davidovici B., Krueger J.G. New insights in the immunologic basis of psoriasis // Semin. Cutan. Med. Surg. 2010. 29. (1). 3–9.
Ogdie A., Schwartzman S., Eder L. et al. Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations // J. Rheumatol. 2014. 41. (11). 2315-2322.
Parisi R., Symmons D.P., Griffiths C.E. et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence // J. Invest. Dermatol. 2013. 133. (2). 377-385.
Patent 2487736 RF. A method for treating of aseptic necrosis of the femoral head / Shusharin A.G., Polovinka M.P., Morozov V.V.; published. 20.07.2013. [In Russian].
Prinz J. The role of T cells in psoriasis // J. Eur. Acad. Dermatol. Venereol. 2003. 17. (3). 257-270.
Punzi L., Podswiadek M., Sfriso P. et al. Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis // Autoimmun. Rev. 2007. 6. 524–528.
Rapp S.R., Feldman S.R., Exum M.L. et al. Psoriasis causes as much disability as other major medical diseases // J. Am. Acad. Dermatol. 1999. 41. (3, Pt. 1). 401-407.
Raychaudhuri S.P., Wilken R., Sukhov A.C. et al. Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies // J. Autoimmun. 2017. 76. 21-37.
Scarpa R., Atteno M., Lubrano E. et al. The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study // Clin. Rheumatol. 2011. 30. 1063–1067.
Schön M.P., Boehncke W.H. Psoriasis // N. Engl. J. Med. 2005. 352. (18). 1899–1912.
Shusharin A.G., Polovinka M.P., Prokhorenko V.M. Estimation of efficiency of conservative treatment aseptic necrosis of the femoral head // Sibirskiy nauchnyy medtsinskiy zhurnal = Siberian Scientific Medical Journal. 2015. 35. (3). 53–58. [In Russian].
Steshenko I.G., Kalyagin A.N. Possibilities of therapy of advanced psoriasis of the skin and psoriatic arthritis with the use of TNF-α blocker (golimumab) // Sovremennye problemy revmatologii = Modern problems of rheumatology. 2014. 6. (6). 57-61. [In Russian].
Sukhov A., Adamopoulos I.E., Maverakis E. Interactions of the immune system with skin and bone tissue in psoriatic arthritis: a comprehensive review // Clin. Rev. Allergy Immunol. 2016. 51. (1). 87-99.